14th European Congress of Clinical Microbiology and Infectious ...

Poster Sessions Sunday, May 2, 2004
P775 Antimicrobial resistance in Salmonella and
Shigella strains isolated from stool cultures
over a 2-year period in Kocaeli, Turkey
S. Günde, H. Üçkarde, A. Willke (Kocaeli, TR)
P776 Transmission and antibiotic resistance
of Campylobacter sp. in a poultry
slaughterhouse
J. Posch, W. Sixl, G. Wüst, S. Schmidt,
F.F. Reinthaler, G. Feierl, E. Marth (Graz, A)
P777 Resistance of Shigella spp. in different
regions of Russia
O. Kretchikova, A. Ivanov, M. Sukhorukova,
L. Stratchounski (Smolensk, RUS)
P778 Campylobacter jejuni and C. coli resistance in
humans, poultry products and farm chickens:
an epidemiological and laboratory study
S. Uzunovic-Kamberovic, T. Zorman, L. Herman,
I. Berce, S. Smole-Mozina (Zenica, BIH; Ljubljana, SI;
Melle, B; Nova Gorica, SI)
13:00–14:00
Linezolid and glycopeptides in Gram-positive
bacterial infection
P779 Oral linezolid as alternative therapy in
patients with cellulitis referred to an infusion
centre
G. Stein, S. Schooley, V. Kak (East Lansing, USA)
P780 Gram-positive bacteria from diabetic foot
ulcers and resistance to second-line
antibiotics (glycopeptides, linezolid,
quinopristin-dalfopristin) in a German
university hospital
S. Monecke, S. Vogel, S. Weber
(Dresden, Hoyerswerda, D)
P781 Effects of oral linezolid treatment in
methicillin-resistant Staphylococcus aureus
colonisation in cystic fibrosis patients
A. Molina, R. Del Campo, L. Máiz, H. Escobar,
F. Baquero, R. Cantón (Madrid, E)
P782 Successful treatment of methicillin-resistant,
teicoplanin-heteroresistant Staphylococcus
aureus prosthetic valve endocarditis with
linezolid
M. Souli, K. Pontikis, Z. Chryssouli, K. Orlandou,
I. Galani, D. Katsala, H. Giamarellou (Chaidari, GR)
P783 The possible role of linezolid in the control of
methicillin-resistant Staphylococcus aureus
outbreaks
I. Pulay, D. Varga Szabó, E. Ungvári, K. Kristóf,
M. Konkoly-Thege (Budapest, HUN)
page 84 Final Programme
P784 Pharmacoeconomic advantages of linezolid
for the treatment of Gram-positive infections
D. Nathwani, S. Duttagupta
(Dundee, UK; New York, USA)
P785 Linezolid vs glycopeptides for the treatment
of suspected or known Gram-positive
infections in critical patients
F. Alvarez-Lerma, M. Palomar, F. Bobillo,
V. González, J. Solé, A. Blanco, C. León –
Study Group for Gram-positive Infections
P786 Linezolid versus vancomycin for cultureproven
complicated skin and soft tissue
infections – trends of subjects enrolled in
Europe and globally in a global study
M. Dryden, N. Chaudry, A. Reisman, J. Weigelt
(Winchester, UK; New York, Milwaukee, USA)
P787 Effects of oral linezolid treatment in
methicillin-resistant Staphylococcus aureus
colonisation in cystic fibrosis patients
A. Molina, R. Del Campo, L. Máiz, H. Escobar,
F. Baquero, R. Cantón (Madrid, E)
P788 In vitro spectrum of linezolid and other
agents against clinical isolates of anaerobes
K. Aldridge, C. Manders, S. Broyles
(New Orleans, USA)
13:00–14:00
Epidemiology of antibiotic susceptibility
P789 Decline in antimicrobial susceptibilities of
anaerobic bacteria from the academic
hospitals in Bloemfontein, South Africa,
1996–2003
P.O. Smith, M.N. Janse van Rensburg, M. Theron
(Bloemfontein, ZA)
P790 Antimicrobial resistance of enteropathogenic
E. coli isolated from rabbits in South Italy
A. Camarda, D. Pennelli, P. Battista, M. Corrente,
I. Alloggio (Valenzano, I)
P791 Frequency and antimicrobial susceptibility
of bacterial pathogens isolated from bloodstream
infections in haematology-oncology
patients: results from the Latin America
SENTRY Antimicrobial Surveillance Program
(1997–2002)
S.S. Andrade, A.C. Gales, H.S. Sader, R.N. Jones,
J.B. Silva, A.C.C. Pignatari and
The Sentry Participants Group – Latin America